INSIGHTS ON CELL & GENE OUTSOURCING ISSUES

• How IntegriCell™ Services In Belgium Ensure Cell Viability, Supply Chain Integrity

  he effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

• Transforming Patient Access To CGT

  Chief Commercial Officer Aruna Mor recently delivered a powerful keynote at the Advanced Therapies Congress in London, highlighting the challenges of patient access to advanced therapies.

• Enabling The Outcome Through Enhancing Patient Accessibility

  To ensure that the transformative potential of cell and gene therapy reaches every patient in need, we must prioritize equitable access and overcome the remaining barriers to widespread delivery.

• How BioServices Centers In France Enable Efficiency And Scalability

  To support the growing demands of the ATMP industry, it's essential to leverage integrated biostorage, sample management, and regulatory solutions, and we are committed to enhancing these capabilities.

• Navigating CGT Biotech's Financial Headwinds And The Path Forward

  Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.

• What CDMOs Wish Biotechs Knew Before Submitting An RFP

  This author has worked with CDMOs across different programs and therapeutic modalities. Each experience reinforced the same lesson: a strong RFP can make or break a partnership.

• 8 Actions To Redefine Sponsor–CDMO Relationships

  When viewing a CDMO as merely a service provider, interactions are often limited to completing tasks. This mindset can stifle innovation and problem-solving.

• Early-Phase Whole-Body PK

  Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

• Label-Free Whole-Body Pharmacokinetics

  This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

• What Is Causing Limited Bioavailability

  Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.